# Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia

> **NCT07755202** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Florian Kuchenbauer** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- AML With FLT3 Mutation

## Interventions

- **COMBINATION_PRODUCT:** gilteritinib-azacitidine-venetoclax

## Key facts

- **NCT ID:** NCT07755202
- **Lead sponsor:** Florian Kuchenbauer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-10-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07755202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07755202, "Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07755202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*